Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: Preliminary results in hepatocellular carcinoma

European Journal of Nuclear Medicine

Volumn 29, Issue 7, 2002, Pages 928-932

  Brans, B ^a   Van Laere, K ^a   Gemmel, F ^a   Defreyne, L ^a   Vanlangenhove, P ^a   Troisi, R ^a   Van Vlierberghe, H ^a   Colle, I ^a   De Hemptinne, B ^a   Dierckx, R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cisplatin; Hepatocellular carcinoma; Intra arterial liver therapy; Iodine 131 Lipiodol; Radiosensitiser

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL; IODINE 131; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT;

ABDOMINAL PAIN; ACUTE ABDOMEN; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; FEMALE; FEVER; FLUID RETENTION; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ULCER; STOMATITIS; TUMOR VOLUME; VOMITING; ADJUVANT CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; MIDDLE AGED; MORTALITY; PILOT STUDY; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGE; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0036655046     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0791-8     Document Type: Article

References (10)

1. Internal radiation therapy for hepatocellular carcinoma: Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol
2. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma
3. Epirubicin-Lipiodol chemotherapy versus iodine-131-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma
4. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy
5. Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: Experience with cis-platinum-based chemoradiotherapy in 76 patients
6. In vitro demonstration of synergy between radionuclide and chemotherapy
7. How should patients with hepatocellular carcinoma be staged: Validation of a new prognostic system
8. The interaction of cisplatin and radiotherapy
9. Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer
10. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy